Flinton Capital Management LLC trimmed its stake in shares of Iterum Therapeutics PLC (NASDAQ:ITRM) by 15.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,552 shares of the company’s stock after selling 6,440 shares during the period. Flinton Capital Management LLC owned about 0.25% of Iterum Therapeutics worth $238,000 at the end of the most recent reporting period.
Shares of ITRM stock opened at $5.96 on Friday. The firm has a market capitalization of $87.39 million, a P/E ratio of -0.84 and a beta of 2.03. The company’s fifty day moving average price is $6.50 and its two-hundred day moving average price is $6.95. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 2.10. Iterum Therapeutics PLC has a 12 month low of $4.70 and a 12 month high of $9.30.
Iterum Therapeutics (NASDAQ:ITRM) last issued its earnings results on Wednesday, August 14th. The company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.43). Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 136.21%. On average, sell-side analysts anticipate that Iterum Therapeutics PLC will post -6.74 EPS for the current year.
Several research firms have commented on ITRM. Zacks Investment Research raised shares of Iterum Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. ValuEngine cut shares of Iterum Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 20th. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Iterum Therapeutics in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $15.75.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Further Reading: Why is momentum important to successful trading?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.